Clinical Trials Browser

Phase 1/2 × Recurrence × Sorafenib × Clear all

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT02530476 2020-03-31

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Phase 1/2 Completed

17 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00536575 2013-02-27

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Phase 1/2 Completed

13 enrolled 5 charts

Plasma cell

Multiple Myeloma, Recurrence

Clinical Trials

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients